View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 21, 2018updated 12 Jul 2022 1:13pm

Viela Bio begins Phase l trial of VIB9600

Viela Bio has initiated a Phase l clinical trial to evaluate the safety and tolerability of VIB9600 for the treatment of adult patients with immune mediated diseases.

Viela Bio has initiated a Phase I clinical trial to evaluate the safety and tolerability of VIB9600 for the treatment of adult patients with immune mediated diseases.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The single-centre, randomised, blinded, placebo-controlled, interventional trial will be conducted in collaboration with CTI Clinical Trial & Consulting.

The first-in-human trial is expected to enrol a maximum of 64 healthy adult subjects enrolled in up to eight groups in the US.

During the trial, the enrolled subjects will receive single and multiple-ascending doses of VIB9600 by intravenous infusion or subcutaneous injection, or placebo.

The primary objective of the trial is safety and tolerability of single and multiple doses of VIB9600 over a period of 113 days.

“After only six months as a company, our people continue to make great strides to advance our pipeline.”

The trial’s secondary objectives include pharmacokinetics (PK) of VIB9600 following single and multiple-dose administration, and immunogenicity of VIB9600 following single and multiple-dose administration as measured by the presence of anti-drug antibodies (ADA) to VIB9600.

The trial, scheduled to be completed by May next year, has started enrolling patients and plans to dose the first patient in the first week of next month.

Viela Bio CEO Bing Yao said: “After only six months as a company, our people continue to make great strides to advance our pipeline.”

Based in Gaithersburg, Maryland, US, Viela Bio is a clinical-stage biotechnology company involved in developing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena